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Innovations
ImmunoGen Inc.
Immunoconjugates in Cancer Therapy: If at First You Don’t
Succeed, Try, Try Again
fect on the patient’s entire body. The the cell were both encoded in the
ricin B chain, leading ImmunoGen’sside effects of this drug are drastic
researchers to design a variant ofand include nausea, vomiting, and
ricin (bR). bR contains intact A andexudative gastritis (inflammation of
B ricin chains; however, through co-the stomach lining).
Monoclonal antibodies, or any class
of immunoglobulin in the body, are
not designed to kill cells. Cytotoxic
“killer” T cells play that role. How-
ever, as a tool to fight cancer, mono-
clonal antibodies have been widely valent modification of the B chain,Since doxorubicin proved to be an
exploited to target tumor cells. Dr. the nonspecific cell surface bindingunattractive drug candidate, Immuno-
Walter Bla¨ttler, Executive Vice Presi- site is abrogated. bR thereforeGen shifted its focus from chemical
dent of ImmunoGen Inc., points out, allows for transport of the highly cy-anticancer agents to the more po-
“Since an antibody is not very well totoxic ricin A chain into selectedtent ribosome-inactivating protein
equipped to kill aberrant cells, one cells (the selectivity is determinedtoxins. Ribosome-inactivating pro-
can give it a mechanism to kill.” By by the associated antibody).teins (RIPs) are N-glycosidases,
conjugating monoclonal antibodies “From a scientific point of view,which catalytically and irreversibly
to any of a variety of cytotoxic drugs, the ideal cell marker would be ex-inactivate eukaryotic ribosomes.
tumor cells can be specifically tar- pressed only on tumor tissues butThese proteins can be extremely cy-
geted for destruction, thereby circum- not on other tissues. But that doestotoxic: one molecule can be
venting the indiscriminate destruction not exist. Instead, there are markersenough to kill a cell. RIPs therefore
of healthy cells and tissues. expressed (at high levels) in tumorhave great potential for the treat-
A directed targeting approach to tissues and at much lower levels inment of cancer. There are two kinds
cancer therapy has been around for normal tissues or (at higher levels)of toxic RIPs, type I and type II. Type
over 20 years, and research has on tissues which are not so impor-I RIPs, such as gelonin, consist of
steadily progressed despite many tant,” explains Bla¨ttler. ImmunoGenone catalytically active “A” peptide
obstacles. Since its inception in conjugated bR to a number of can-
1981, ImmunoGen Inc. has focused cer cell marker antibodies: anti-CD6
on achieving more effective and bet- (chronic B-lymphocytic leukemias),
“From a scientific point ofter-tolerated therapies for the treat- anti-CD33 (acute myeloid leukemia
[AML] cells), anti-CD38 (acute lymph-ment of cancer. The company’s tri- view, the ideal cell marker
als, tribulations, and successes over ocytic leukemia [ALL] and AML),would be expressed only
the last 22 years make for a good anti-N901 (small cell lung carcinoma
on tumor tissues, but notstory of scientific discovery, forti- [SCLC]). and anti-B4 (B lineage leu-
kemia, B cell non-Hodgkin’s lym-tude, and resolve. on other tissues.” – Dr.
In the early 1980s, ImmunoGen phoma and AIDS-related non-Hodg-Walter Bla¨ttler, Executive
worked with the chemotherapy kin’s lymphoma [ARL]). The various
V.P., ImmunoGen Inc.agent doxorubicin crosslinked to antibody blocked-ricin immunocon-
monoclonal antibodies specific for jugates had varying levels of effi-
cancer cells. Doxorubicin binds to cacy, with anti-B4-bR reaching
chain, whereas type II toxins, suchDNA and inhibits the essential en- phase III clinical trials. In preclinical
as ricin, the main toxic protein in thezyme topoisomerase II, resulting in studies, the bR conjugates were ad-
castor bean plant Ricinus commu-a block in DNA replication and ulti- ministered in immune-compromised
nis, are composed of an “A” peptidemately cell death. Within one year of animals and patients. Under these
and a distinct “B” chain. It wasintensive analysis, ImmunoGen de- suppressive conditions, the bR con-
known that the A peptide containedtermined that doxorubicin was not jugates proved to be efficient agents
the catalytic moiety, while the Bsufficiently potent when linked to for relatively specific destruction of
chain encoded the binding site formonoclonal antibodies to reach and cancer cells. However, in the major-
galactose residues which are abun-effectively destroy a tumor. This ity of cancer patients who are not
dant at cell surfaces. To avoid theproject was subsequently aban- immunosuppressed, the ricin pro-
indiscriminate cell surface bindingdoned; however, other companies tein conjugated to any antibody was
of the ricin B chain, ImmunoGen de-have pursued doxorubicin, which highly immunogenic. Hence, Immuno-
signed an antibody conjugated tohas been widely used as a chemo- Gen’s pursuit of an anticancer con-
the catalytic ricin A chain alone. Un-therapy drug and is most commonly jugate linked to ricin ended.
fortunately, this conjugate did notknown by the brand name Adriamy- In parallel with the ricin conjugate
kill cells efficiently. Consequently, itcin. Adriamycin destroys dividing program, ImmunoGen was generat-
was discovered that both the cellcells and thus has some effect on ing type I RIP conjugates, primarily
surface binding domain and the ma-cancer cells; however, it also has a using gelonin and pokeweed antivi-
ral protein (PAP). However, thesewidespread and indiscriminate ef- chinery to introduce the A chain into
Chemistry & Biology
782
plant toxin immunoconjugates were residues are replaced with amino In addition to the low global toxicity
of the conjugate, an advantage of thenot effective cell killers, since the acids from the corresponding loca-
structure is the free sulfhydryl groupconjugated antibody could not effi- tion in the human antibody variable
of DM1 that enabled stable disulfideciently transport the toxin into cells, region. If the substitution results in
linkage to the huC242 antibody. Theand the gelonin and PAP toxins reduced binding affinity, the resi-
disulfide linkage stabilizes DM1 incould not access the cancer cells dues are “back-mutated” to the mu-
the bloodstream, rendering it inac-that they were intended to destroy. rine state to reinstate the high-affin-
tive. But upon recognition of Muc1In the early 1990s, a crucial obser- ity binding associated with the
by the huC242 antibody, the entirevation was made before abandoning original murine antibody. High-affin-
complex is internalized and DM1 isthe unsuccessful antibody-toxin con- ity humanized murine variable re-
released in the cell by proteolyticjugate program. Researchers reported gions are then joined with constant
cleavage of the DM1-huC242 disul-that in humans the immunoconju- regions from human antibodies to
fide bond.gates induced a severe immune re- generate stable hybrids. The prem-
ImmunoGen named their anti-sponse directed against the protein ise behind a “resurfacing” approach
body-drug conjugates tumor-acti-toxin and the mouse monoclonal an- stems from the origin of immunoge-
vated prodrugs (TAPs) since thetibody. The latter type is known as a nicity, which is directly correlated
conjugates were not toxic to cellshuman anti-mouse antibody (HAMA) with the nature of surface residues
lacking the target antigen. The DM1-response. As a means of clearing of proteins. In fact, surfaces carry
Muc1 conjugate, referred to as anti-this obstacle, ImmunoGen began to most if not all of the antigenic poten-
CanAg-DM1 TAP, is presently un-develop means to “humanize” mono- tial of the protein.
dergoing phase II clinical trials, andclonal antibodies. However, Immuno- Antibody resurfacing had been
trials have also begun with otherGen was not alone in its quest to en- established for several years by the
DM1 conjugates. BB-10901 TAPgineer monoclonal antibodies with time the protein toxin conjugate
(huN901-DM1) targets CD56, whichcrucial human-like traits. Several studies were finally ended. With their
is expressed on small cell lung carci-laboratories recognized the clinical pipeline of potential drugs wiped out
noma (SCLC) and tumors of neuro-limitations of murine antibodies, and and the humanized antibody in
endocrine origin. There are alsoconsequently there are now several hand, ImmunoGen regrouped and
DM1 TAP conjugates targeting pros-
different strategies for generating pushed forward. From previous
tate-specific membrane antigen
human or human-like antibodies. studies on cytotoxic “nonprotein”
(PSMA) for the treatment of prostate
An early approach for antibody compounds, ImmunoGen reevalu- cancer and CD44v6-expressing solid
humanization focused on reducing ated the molecules reported to have tumors. An anti-CD33-DM1 conjugate
the immunogenicity of murine IgGs the highest cytotoxicity. Maytan- that targets AML cells is currently in
by incorporating key residues char- sine, an antimicrotubule agent, was preclinical development.
acteristic of human antibodies, re- at the top of the potency list. The With their pipeline full and flow-
sulting in approximately 75% human anticancer properties of Maytansine ing, it’s no wonder that ImmunoGen
chimeric antibodies. When tested in had been investigated by the Na- recently made a deal with Aventis.
immunosuppressed patients, the tional Cancer Institute in the 1970s, Aventis, France’s largest drug maker,
chimeric antibodies had limited im- and during testing in phase I and II will pay ImmunoGen $12 million up-
munogenicity but were still highly clinical trials maytansine treatment front and $50 million to fund research
immunogenic in patients with nor- resulted in complete and partial re- over the next three years, allowing
mal immune systems. gression in a few patients with differ- ImmunoGen to continue and expand
A more advanced tactic was ex- ent forms of cancer. However, its se- its research. However, the company
plored to transfer the antigen speci- vere toxic effects precluded further cannot rest on its laurels just yet;
ficity and binding avidity of murine study at that time. one cannot truly predict the final effi-
monoclonal antibodies to a human ImmunoGen believed the ex- cacy of these prodrugs prior to
antibody: the murine complementar- tremely potent properties of may- phase III trials. As Bla¨ttler points out,
ity-determining regions or CDRs (the tansine to be ideal for creating tumor- “These diseases are very heteroge-
antibody domain that binds the anti- specific antibody-drug conjugates. nous. In AML, there isn’t just one
gen) were grafted onto a human vari- To this end, four molecules of a tumor lesion, there are many. One
able region framework. However, chemical derivative of maytansine, never knows exactly why one drug
CDR grafting can require additional DM1, which is 3- to 10-fold more will be effective.” It seems that Im-
amino acid changes within the hu- potent than maytansine, were conju- munoGen’s history of dedicated
man framework to preserve proper gated to the humanized monoclonal cancer research will help them clear
binding affinities, and such changes antibody huC242. Anti-huC242 binds further hurdles on their journey to-
in the human variable region can pro- specifically to a glycoform of the ward effective cancer therapies.
duce troublesome antigenic epitopes. Muc1 carbohydrate that is highly ex-
Chemistry & Biology invites yourImmunoGen learned from these pressed in most pancreatic, biliary,
comments on this topic. Pleasemistakes and embraced a novel and colorectal cancers as well as in
write to the editors at chembiol@knowledge-based approach termed a large proportion of nonsmall cell
cell.com.variable domain resurfacing that uses lung (40%) gastric (55%), uterine
(45%), and bladder (40%) cancers.computer modeling to identify sur- Nicole Ballew is a freelance science writer
face residues within the variable re- Fortunately, Muc1 is minimally ex- from Lebanon, NH and can be contacted at
nballew@hotmail.com.gion of the murine antibody. Surface pressed in normal tissues and cells.
